Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Norihito, Inoue"'
Autor:
Kei Hirano, Kikuaki Yoshida, Norihito Inoue, Naoko Tsuyama, Yukako Teramoto, Mitsuhito Hirano, Mikako Tanba, Nobuhiko Yamauchi, Yuko Shirouchi, Yuko Ishihara, Hiroaki Asai, Yuko Mishima, Senzo Taguchi, Toshiaki Hirasawa, Kengo Takeuchi, Dai Maruyama
Publikováno v:
HemaSphere, Vol 7, p e64794e6 (2023)
Externí odkaz:
https://doaj.org/article/4ec6a20124cf49cf9343b472a2ea21b5
Autor:
Masahiro Yokoyama, Yoshiharu Kusano, Norihito Inoue, Noriko Nishimura, Yuko Mishima, Tomoyuki Nukada, Kiyohiko Hatake, Yasuhito Terui
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background A classification tree was used to analyze background factors for granulocyte colony-stimulating factor (G-CSF) preparation selection for febrile neutropenia (FN) prophylaxis in Japanese patients with non-Hodgkin B-cell lymphoma re
Externí odkaz:
https://doaj.org/article/c104cb09f17a477da0b8915bcb699586
Diffuse large B‐cell lymphoma arising immediately after completion of treatment for Hodgkin lymphoma
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 883-884 (2021)
Externí odkaz:
https://doaj.org/article/2f9fe91391c34bd586a7cfbd4c9ec766
Autor:
Mitsuhito Hirano, Mikako Tamba, Norihito Inoue, Michiru Ikegami, Naoki Onda, Yuko Shirouchi, Yuko Ishihara, Hitoshi Abe, Noriko Nishimura, Yuko Mishima, Kengo Takeuchi, Dai Maruyama
Publikováno v:
Annals of Hematology. 101:1587-1589
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc006a45351f571e6c715496bb151095
https://doi.org/10.1007/s00277-022-04777-z
https://doi.org/10.1007/s00277-022-04777-z
Autor:
Masahiro Yokoyama, Yuko Shirouchi, Norihito Inoue, Noriko Nishimura, Hideki Uryu, Yasuhito Terui, Naoko Tsuyama, Takanori Fukuta, Kengo Takeuchi, Takashi Okabe, Yuko Mishima
Publikováno v:
Leukemia & Lymphoma. 62:2141-2150
Although outcomes of transformed diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) were improved using rituximab-combined immunochemotherapy, the efficacy of subsequent rituximab maintenance (RM) remains unclear. We retrospectively
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25fc10f0a2f7a689c1c4ff2ab113c4bd
https://doi.org/10.1080/10428194.2021.1901091
https://doi.org/10.1080/10428194.2021.1901091
Autor:
Norihito Inoue, Kengo Takeuchi, Yuko Mishima, Yuko Shirouchi, Masahiro Yokoyama, Hideki Uryu, Takanori Fukuta, Naoko Tsuyama, Yasuhito Terui, Noriko Nishimura
Publikováno v:
Leukemia & Lymphoma. 62:1869-1876
Peripheral T-cell lymphoma (PTCL) is a group of aggressive lymphomas commonly treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Progression-free survival at 24 months (PFS24) constitutes a survival predictor for some lym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b678b91981f4d6a7118916e72cf42c38
https://doi.org/10.1080/10428194.2021.1894649
https://doi.org/10.1080/10428194.2021.1894649
Autor:
Norihito Inoue, Noriko Nishimura, Yasuhito Terui, Takashi Okabe, Yuji Mishima, Yuko Mishima, Masahiro Yokoyama, Hideki Uryu, Takanori Fukuta, Yuko Shirouchi, Kiyohiko Hatake
Publikováno v:
International Journal of Hematology. 113:279-284
Somatic gene mutations related to acceleration disease and clonal evolution in multiple myeloma strongly influence severe clinical outcomes. In this study, we traced the transition of somatic mutations during the clinical course of myeloma patients o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2aad2b5e2169a293f135b9641677eab
https://doi.org/10.1007/s12185-020-02979-7
https://doi.org/10.1007/s12185-020-02979-7
Autor:
Noriko Nishimura, Yasuhito Terui, Kiyohiko Hatake, Norihito Inoue, Yoshiharu Kusano, Masahiro Yokoyama, Takanobu Nomura, Yuko Mishima, Tomoyuki Nukada, Anna Nishihara
Publikováno v:
Supportive Care in Cancer
Background Myelosuppressive chemotherapy-induced febrile neutropenia (FN) is a life-threatening condition. Patients receiving granulocyte colony-stimulating factors (G-CSF) have shorter duration of neutropenia, faster recovery from fever, and shorter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbaaa7584fe09b18986be9e6b999e400
https://doi.org/10.1007/s00520-019-04802-4
https://doi.org/10.1007/s00520-019-04802-4
Autor:
Hideki, Uryu, Yuko, Mishima, Naoko, Tsuyama, Masahiro, Yokoyama, Noriko, Nishimura, Takanori, Fukuta, Yuko, Shirouchi, Takashi, Okabe, Norihito, Inoue, Kengo, Takeuchi, Yasuhito, Terui
Publikováno v:
Leukemialymphoma. 62(9)
Although outcomes of transformed diffuse large B-cell lymphoma (DLBCL) from follicular lymphoma (FL) were improved using rituximab-combined immunochemotherapy, the efficacy of subsequent rituximab maintenance (RM) remains unclear. We retrospectively
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ce71920fbd9bf5bf9c59a37c63df37af
https://pubmed.ncbi.nlm.nih.gov/33749498
https://pubmed.ncbi.nlm.nih.gov/33749498